Highlighting Germany's biotech clusters.
All locations are close to university facilities, clinics and research and start-up hubs. They can be conveniently reached thanks to excellent access to public transportation.
Locations
LOCATIONS
Aventin Real Estate designs and develops R&D buildings in established life sciences hotspots throughout Germany. In addition to Munich and Berlin, we primarily focus on established university cities and locations that are home to renowned research institutes.
References
Dr. Thomas Meins, Site Head and Managing Director of CRELUX GmbH – a WuXi AppTec company
“The excellent collaboration with Aventin during the entire planning and construction phase was essential to realize a state-of-the-art life science building that not only accommodates Crelux’s current growth, but also sets the stage for future developments. Thanks to the customized spatial and technical infrastructure, several operative units of WuXi Biology and LTD can now work side by side in the center of the Munich biotech community to further expand WuXi AppTec’s Open Service Platform, already enabling thousands of innovative clients around the globe."
Federico Buersgens, Managing Director HP Health Solutions Germany
“OUR new laboratories in the Life Science Centre offer us an inspiring and collaborative working environment that promotes creativity and productivity. Equipped with state-of-the-art technology, our colleagues are able to perform their work at the highest level and develop new products and applications.”
Tobias Gabriel, Ph.D., Vice President and Head of WuXi AppTec Europe
"We would like to thank Aventin for the dedicated efforts in establishing the state-of-the-art infrastructure. Moving to the Life Science Center Gräfelfing marks a key step forward for WuXi AppTec. It allows us to provide expanded capabilities of structure-based drug discovery and lab testing under one roof, further enhancing our services to the European pharmaceutical industry and beyond. Through the unique CRDMO (Contract Research, Development and Manufacturing Organization) business model, we are looking forward to continuing to help our customers advance life-saving treatments and medicines faster for patients around the world."